vs

Side-by-side financial comparison of Almonty Industries Inc. (ALM) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.

Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $6.3M, roughly 1.8× Almonty Industries Inc.). Almonty Industries Inc. runs the higher net margin — -86.1% vs -667.6%, a 581.6% gap on every dollar of revenue.

Almonty Industries Inc. is an international mining company primarily engaged in the extraction and development of tungsten resources. The company operates in Spain, Portugal, and South Korea and is publicly traded on the Toronto Stock Exchange (TSX). The current Chief Executive Officer is Lewis Black.

Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.

ALM vs KYMR — Head-to-Head

Bigger by revenue
KYMR
KYMR
1.8× larger
KYMR
$11.5M
$6.3M
ALM
Higher net margin
ALM
ALM
581.6% more per $
ALM
-86.1%
-667.6%
KYMR

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
ALM
ALM
KYMR
KYMR
Revenue
$6.3M
$11.5M
Net Profit
$-5.4M
$-76.6M
Gross Margin
Operating Margin
-736.8%
Net Margin
-86.1%
-667.6%
Revenue YoY
-55.3%
Net Profit YoY
-82.1%
EPS (diluted)
$-0.95

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALM
ALM
KYMR
KYMR
Q3 25
$6.3M
Q2 25
$7.2M
$11.5M
Q1 25
$22.1M
Q4 24
$7.4M
Q2 24
$25.6M
Q1 24
$10.3M
Q4 23
$47.9M
Q2 23
$16.5M
Net Profit
ALM
ALM
KYMR
KYMR
Q3 25
$-5.4M
Q2 25
$-58.2M
$-76.6M
Q1 25
$-65.6M
Q4 24
$-70.8M
Q2 24
$-42.1M
Q1 24
$-48.6M
Q4 23
$-14.4M
Q2 23
$-38.8M
Operating Margin
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
-736.8%
Q1 25
-336.8%
Q4 24
-1092.2%
Q2 24
-198.5%
Q1 24
-562.2%
Q4 23
-40.3%
Q2 23
-262.7%
Net Margin
ALM
ALM
KYMR
KYMR
Q3 25
-86.1%
Q2 25
-809.4%
-667.6%
Q1 25
-296.7%
Q4 24
-956.9%
Q2 24
-164.0%
Q1 24
-472.0%
Q4 23
-30.0%
Q2 23
-235.0%
EPS (diluted)
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$-0.95
Q1 25
$-0.82
Q4 24
$-0.89
Q2 24
$-0.58
Q1 24
$-0.69
Q4 23
$-0.25
Q2 23
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALM
ALM
KYMR
KYMR
Cash + ST InvestmentsLiquidity on hand
$335.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$971.5M
Total Assets
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$335.8M
Q1 25
$90.0M
Q4 24
$120.3M
Q2 24
$67.6M
Q1 24
$93.5M
Q4 23
$110.0M
Q2 23
$52.4M
Stockholders' Equity
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$971.5M
Q1 25
$786.2M
Q4 24
$835.6M
Q2 24
$684.9M
Q1 24
$711.2M
Q4 23
$395.0M
Q2 23
$435.4M
Total Assets
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$1.1B
Q1 25
$918.3M
Q4 24
$978.0M
Q2 24
$826.0M
Q1 24
$868.3M
Q4 23
$575.8M
Q2 23
$581.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALM
ALM
KYMR
KYMR
Operating Cash FlowLast quarter
$-59.9M
Free Cash FlowOCF − Capex
$-60.6M
FCF MarginFCF / Revenue
-527.9%
Capex IntensityCapex / Revenue
6.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-250.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$-59.9M
Q1 25
$-79.2M
Q4 24
$-61.8M
Q2 24
$-42.9M
Q1 24
$-39.6M
Q4 23
$8.0M
Q2 23
$-35.3M
Free Cash Flow
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
$-60.6M
Q1 25
$-79.6M
Q4 24
$-62.7M
Q2 24
$-47.6M
Q1 24
$-47.0M
Q4 23
$-3.6M
Q2 23
$-46.0M
FCF Margin
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
-527.9%
Q1 25
-360.3%
Q4 24
-848.3%
Q2 24
-185.7%
Q1 24
-456.8%
Q4 23
-7.5%
Q2 23
-278.7%
Capex Intensity
ALM
ALM
KYMR
KYMR
Q3 25
Q2 25
6.1%
Q1 25
2.1%
Q4 24
12.7%
Q2 24
18.3%
Q1 24
72.0%
Q4 23
24.3%
Q2 23
65.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons